Compare Monolithic Power Systems Inc (MPWR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Viatris Inc — how do they compare? Monolithic Power Systems Inc trades at $1,399.99 (market cap $70.08B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Monolithic Power Systems Inc is far larger — about 3.5× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.74%). Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Viatris Inc for 57 Days on average.
| MPWR | VTRS | |
|---|---|---|
Market Cap | $70.08B | $20.12B |
Volume | 480,594 | 7,543,511 |
Sector | Technology | Health |
52-Week High | $1.69K | $18.27 |
52-Week Low | $856.96 | $9.74 |
Typical Hold Time | 25 Days | 57 Days |
Enterprise Value | $68.68B | $32.24B |
Dividend Yield | 0.56% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,425.98, down 3.24% on the day, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 24.5% net income margin and 21.98% ROE, though valuation metrics remain elevated at 87 P/E. Recent earnings beats and a manufacturing partnership with GlobalFoundries signal continued growth potential in AI and data center markets.
MPWR presents a compelling growth story driven by AI infrastructure demand, but faces valuation concerns and insider selling pressure. The stock's 88% buy rating consensus and $1,830 price target suggest 28% upside potential, though investors should weigh premium valuation against strong execution and market positioning.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
